463 related articles for article (PubMed ID: 22860209)
1. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
Sagredo O; Pazos MR; Satta V; Ramos JA; Pertwee RG; Fernández-Ruiz J
J Neurosci Res; 2011 Sep; 89(9):1509-18. PubMed ID: 21674569
[TBL] [Abstract][Full Text] [Related]
3. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
[TBL] [Abstract][Full Text] [Related]
4. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
Sagredo O; González S; Aroyo I; Pazos MR; Benito C; Lastres-Becker I; Romero JP; Tolón RM; Mechoulam R; Brouillet E; Romero J; Fernández-Ruiz J
Glia; 2009 Aug; 57(11):1154-67. PubMed ID: 19115380
[TBL] [Abstract][Full Text] [Related]
6. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Lastres-Becker I; Bizat N; Boyer F; Hantraye P; Brouillet E; Fernández-Ruiz J
Neuroreport; 2003 May; 14(6):813-6. PubMed ID: 12858038
[TBL] [Abstract][Full Text] [Related]
7. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.
Moreno-Martet M; Espejo-Porras F; Fernández-Ruiz J; de Lago E
CNS Neurosci Ther; 2014 Sep; 20(9):809-15. PubMed ID: 24703394
[TBL] [Abstract][Full Text] [Related]
8. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C
Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324
[TBL] [Abstract][Full Text] [Related]
9. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
[TBL] [Abstract][Full Text] [Related]
12. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
[TBL] [Abstract][Full Text] [Related]
13. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.
Valdeolivas S; Pazos MR; Bisogno T; Piscitelli F; Iannotti FA; Allarà M; Sagredo O; Di Marzo V; Fernández-Ruiz J
Cell Death Dis; 2013 Oct; 4(10):e862. PubMed ID: 24136226
[TBL] [Abstract][Full Text] [Related]
15. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids: novel medicines for the treatment of Huntington's disease.
Sagredo O; Pazos MR; Valdeolivas S; Fernandez-Ruiz J
Recent Pat CNS Drug Discov; 2012 Apr; 7(1):41-8. PubMed ID: 22280340
[TBL] [Abstract][Full Text] [Related]
17. Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
Pertwee RG
Br J Pharmacol; 2009 Feb; 156(3):397-411. PubMed ID: 19226257
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
20. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
